Rapid Medical’s Tigertriever 13 Thrombectomy Device Gains FDA Clearance

July 25, 2022—Rapid Medical, a developer of neurovascular devices, announced FDA 510(k) clearance for Tigertriever 13 for large vessel occlusions at the 19th annual meeting of the Society of NeuroInterventional Surgery, held July 25-29 in Toronto, Canada.

Tigertriever 13 is a small revascularization device that is designed to remove thrombus from delicate brain blood vessels during an ischemic stroke. The device adjusts to the vasculature and clot to provide a more atraumatic approach.

“The neurovascular field has been waiting for a thrombectomy device dedicated to small vessels,” commented David Fiorella, MD, in the company’s press release. “Medical therapy is currently suboptimal for these patients, so there can be a huge benefit for devices that emergently restore blood flow while minimizing the potential for harm.” Dr. Fiorella is from Stony Brook University Medical Center in Stony Brook, New York.

According to the company, the Tigertriever portfolio’s adjustability comes from complex three-dimensional braiding borrowed from recent advances in aerospace engineering. Tigertriever is precisely controlled to capture the thrombus and remove the tension from the vasculature before removal. Also, adjustability gives Tigertriever 13 stent retriever provides a low profile—24% smaller than 3-mm devices, allowing easier navigation in challenging anatomies. The ability to tailor each procedure can provide new safety levels for higher risk thrombectomies, stated Rapid Medical.